Merck Slips 5% on the Week as Analysts Hold Bullish but Trim Targets

The most notable analyst moves bracket the week from both sides. On October 7, Morgan Stanley's Terence Flynn trimmed his target by $2 to $177 while holding Overweight. A day earlier, JP Morgan's Chris Schott went the other direction, lifting his target to $165 from $150, also maintaining Overweight. Both actions land within 14 days and both are from bellwether firms, so they deserve the attention: one house is cooling slightly, the other is adding conviction, and neither is walking away from a positive rating. The broader analyst trend since late August has been unambiguously higher targets, with Scotiabank at $180, Wolfe Research at $180, HSBC at $172, and Goldman Sachs at $160, all raises and no downgrades in the cycle. The mean target of $156.28 still looks conservative relative to where the active updaters are anchoring. The bull case rests on late-stage pipeline momentum, including intismeran autogene and sacituzumab tirumotecan, plus Winrevair and HIV assets, while the bear case centres on Keytruda replacement risk, a $400 million charge from the SciBrunch license, and near-term Ohtuvayre revenue disruption from a specialty pharmacy unwind.

Positioning in the lending market gives no independent signal worth trading around. Short interest is just 1.2% of the free float, up about 17% over the past month in share terms, but from a very low base. Availability is essentially uncapped, with shares to borrow far exceeding current demand, so there is no squeeze mechanics at play and no evidence that bears are pressing a serious thesis through the borrow market. Cost to borrow has nearly tripled over the week to 0.37%, but in absolute terms that remains negligible. The ORTEX short score of 31 is consistent with a lightly shorted name. Factor scores show an earnings-surprise rank in the 91st percentile, a dividend score at the 94th percentile, and a days-to-cover rank of 75, all pointing to a high-quality, well-covered stock with no meaningful short-side tension. Options are equally benign: the put/call ratio eased to 0.77 on October 6, modestly below its 20-day average of 0.79 and well within one standard deviation of normal. There is no elevated hedging demand visible ahead of the earnings date.

On the alt data front, Medicaid prescription volumes for Merck products were running 22% below the same quarter a year earlier as of Q1 2026, with Medicaid units reimbursed also down 16% year-on-year in that period. Neither dataset has been shown to lead Merck's reported financials, so these readings describe the Medicaid channel specifically rather than group-level revenue. The decline likely reflects mix changes in the payer base and product-level dynamics rather than a broad commercial deterioration, but it is worth carrying into the Q3 conversation as context for channel performance.

With the Q3 print scheduled for October 29, the twenty-two days remaining will focus attention on whether Keytruda trends, the Ohtuvayre inventory normalisation, and any update on the revenue hedging programme can meet the high target prices analysts have been steadily raising toward all autumn.